FOLH1 and prostate cancer: MRI in combination with prostate-specific membrane antigen positron emission tomography can reduce false negatives for clinically significant prostate cancer (csPCa) compared with MRI, potentially reducing the number of prostate biopsies required to diagnose csPCa [70].